ASTM E3263-20
(Practice)Standard Practice for Qualification of Visual Inspection of Pharmaceutical Manufacturing Equipment and Medical Devices for Residues
Standard Practice for Qualification of Visual Inspection of Pharmaceutical Manufacturing Equipment and Medical Devices for Residues
SIGNIFICANCE AND USE
4.1 Application of the approach described within this practice applies the science-based, risk-based, and statistics-based concepts and principles introduced in Guides E3106 and E3219.
4.2 Application of the approach described within this practice provides a science-, risk-, and statistical-based approach for qualifying the inspection of equipment for cleanliness in accordance with 21 CFR 211.67(b)(6).
4.3 Application of the approach described within this practice provides a science-, risk-, and statistical-based approach for qualifying the visual inspection of equipment for cleanliness in accordance with European Medicines Agency (EMA) Annex 15 (2).
4.4 Application of the approach described within this practice provides a science-, risk-, and statistical-based approach for qualifying the visual inspection of equipment for cleanliness in accordance with the EMA’s Q&A Guidance (Q&A’s #7 and #8) (2).
4.5 Application of the approach described within this practice applies the risk-based concepts and principles introduced in ICH Q9. As stated in ICH Q9, the level of effort, formality, and documentation for validation (including cleaning validation) should also be commensurate with the level of risk.
4.6 Application of the approach described within this practice provides a science-, risk-, and statistical-based approach for releasing manufacturing equipment and manufactured medical devices or cleanliness that is compatible with the U.S. FDA Guidance on Process Analytical Technology Initiative (3).
4.7 Key Concepts—This practice applies the following key concepts: (1) visual inspection, (2) quality risk management, (3) science-based approach, (4) statistics-based approach, and (5) process knowledge and understanding.
SCOPE
1.1 This practice provides statistically valid procedures for determining the visual detection limit of residues and the qualification of inspectors to perform the visual inspection of pharmaceutical manufacturing equipment surfaces and medical devices for residues.
1.2 This practice applies to pharmaceuticals [including active pharmaceutical ingredients (APIs); dosage forms; and over-the-counter, veterinary, biologics, and clinical supplies] and medical devices following all manufacturing and cleaning. This practice is also applicable to other health, cosmetics, and consumer products.
1.3 This practice applies to all types of chemical residues (including APIs, intermediates, cleaning agents, processing aids, machining oils, and so forth) that could remain on manufacturing equipment surfaces or medical devices that have undergone all manufacturing steps including cleaning.
1.4 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.
1.5 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.
1.6 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
General Information
Standards Content (Sample)
NOTICE: This standard has either been superseded and replaced by a new version or withdrawn.
Contact ASTM International (www.astm.org) for the latest information
Designation:E3263 −20
Standard Practice for
Qualification of Visual Inspection of Pharmaceutical
Manufacturing Equipment and Medical Devices for
1
Residues
This standard is issued under the fixed designation E3263; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision.Anumber in parentheses indicates the year of last reapproval.A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope 2. Referenced Documents
2
1.1 This practice provides statistically valid procedures for 2.1 ASTM Standards:
determining the visual detection limit of residues and the E2782Guide for Measurement Systems Analysis (MSA)
qualification of inspectors to perform the visual inspection of E3106Guide for Science-Based and Risk-Based Cleaning
pharmaceuticalmanufacturingequipmentsurfacesandmedical Process Development and Validation
devices for residues. E3219GuideforDerivationofHealth-BasedExposureLim-
its (HBELs)
1.2 This practice applies to pharmaceuticals [including ac-
G121Practice for Preparation of Contaminated Test Cou-
tive pharmaceutical ingredients (APIs); dosage forms; and
pons for the Evaluation of Cleaning Agents
over-the-counter, veterinary, biologics, and clinical supplies]
3
2.2 ICH Guidance:
andmedicaldevicesfollowingallmanufacturingandcleaning.
ICH Q9Quality Risk Management
This practice is also applicable to other health, cosmetics, and
4
2.3 ISO Standard:
consumer products.
EN 12464Light and lighting—Lighting of workplaces—
1.3 This practice applies to all types of chemical residues
Indoor workplaces
(including APIs, intermediates, cleaning agents, processing
2.4 Federal Regulation:
5
aids, machining oils, and so forth) that could remain on
21 CFR 211.67Equipment Cleaning and Maintenance
manufacturing equipment surfaces or medical devices that
2.5 European Regulation:
have undergone all manufacturing steps including cleaning.
EudraLex Volume 4Guidelines for Good Manufacturing
Practices for Medicinal Products for Human and Veteri-
1.4 The values stated in SI units are to be regarded as
6
standard. No other units of measurement are included in this nary Use, Annex 15: Qualification and Validation
7
2.6 FDA Standard:
standard.
Guidance for Industry PATA Framework for Innovative
1.5 This standard does not purport to address all of the
Pharmaceutical Development, Manufacturing, and Qual-
safety concerns, if any, associated with its use. It is the
ity Assurance
responsibility of the user of this standard to establish appro-
priate safety, health, and environmental practices and deter-
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or
mine the applicability of regulatory limitations prior to use.
contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM
1.6 This international standard was developed in accor-
Standards volume information, refer to the standard’s Document Summary page on
dance with internationally recognized principles on standard-
the ASTM website.
3
ization established in the Decision on Principles for the Available from International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH
Development of International Standards, Guides and Recom-
Secretariat, 9, chemin des Mines, P.O. Box 195, 1211 Geneva 20, Switzerland,
mendations issued by the World Trade Organization Technical
http://www.ich.org.
4
Barriers to Trade (TBT) Committee.
Available fromAmerican National Standards Institute (ANSI), 25 W. 43rd St.,
4th Floor, New York, NY 10036, http://www.ansi.org.
5
Available from U.S. Government Printing Office, Superintendent of
1
This practice is under the jurisdiction of ASTM Committee E55 on Manufac- Documents, 732 N. Capitol St., NW, Washington, DC 20401-0001, http://
ture of Pharmaceutical and Biopharmaceutical Products and is the direct responsi- www.access.gpo.gov.
6
bility of Subcommittee E55.03 on General Pharmaceutical Standards. Available from https://ec.europa.eu/health/documents/eudralex/vol-4_en
7
Current edition approved Oct. 1, 2020. Published November 2020. DOI: Available from U.S. Food and Drug Administration (FDA), 10903 New
10.1520/E3263-20. Hampshire Ave., Silver Spring, MD 20993, http://www.fda.gov.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1
---------------------- Page: 1 ----------------------
E3263−20
3. Terminology 3.1.10 maximum safe surface residue, MSSR, n—maximum
amount of residual process residue (API, cleaning agent,
3.1 Definitions:
degradant, and so forth) that may remain on manufacturing
3.1.1 cleaning process residue, n—any residue, including,
equipment or medical device surfaces without presenting an
but not l
...
Questions, Comments and Discussion
Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.